Boris Reva

Mount Sinai Hospital — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

44h-index51.1kcitations160works16.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

RNA modifications and cancer(32), Cancer Genomics and Diagnostics(31), Lung Cancer Treatments and Mutations(27), Epigenetics and DNA Methylation(24), Protein Structure and Dynamics(23)

Publications151 total

Prostate cancer in situ autovaccination with the intratumoral viral mimic poly-ICLC: Modulating the cold tumor microenvironment
Med·2025Open Access
MutationAssessor in cBioPortal
2025· 1 citedOpen Access
Abstract 5104: Fibrosis activates pancreatic cancer Schwann cells in a non-canonical pathway through a nuclear mechanosensing mechanism
Cancer Research·2025
Comprehensive proteogenomic characterization of rare kidney tumors
Cell Reports Medicine·2024· 39 citedOpen Access
Abstract CT023: Prostate cancer in situ autovaccination with the intratumoral viral mimic poly-ICLC: Making a cold tumor hot
Cancer Research·2024· 3 cited
Mutations in cancer-relevant genes are ubiquitous in histologically normal endometrial tissue
Gynecologic Oncology·2024· 5 cited
Pan-cancer proteogenomics characterization of tumor immunity
Cell·2024· 76 citedOpen Access
Proteogenomic analysis of chemo-refractory high-grade serous ovarian cancer
Cell·2024· 8 citedOpen Access
Integrative multi-omic cancer profiling reveals DNA methylation patterns associated with therapeutic vulnerability and cell-of-origin
Cancer Cell·2023· 90 citedOpen Access
Deep learning integrates histopathology and proteogenomics at a pan-cancer level
Cell Reports Medicine·2023· 30 citedOpen Access
Proteogenomic insights suggest druggable pathways in endometrial carcinoma
Cancer Cell·2023· 44 citedOpen Access
Proteogenomic data and resources for pan-cancer analysis
Cancer Cell·2023· 197 citedOpen Access
Proteogenomic analysis of chemo-refractory high-grade serous ovarian cancer
Cell·2023· 83 citedOpen Access
Pan-cancer analysis of post-translational modifications reveals shared patterns of protein regulation
Cell·2023· 156 citedOpen Access
Pan-cancer proteogenomics connects oncogenic drivers to functional states
Cell·2023· 92 citedOpen Access
Supplementary Figure 2 from <i>EGFR</i> Exon 20 Insertion Mutations in Lung Adenocarcinomas: Prevalence, Molecular Heterogeneity, and Clinicopathologic Characteristics
2023Open Access
Supplementary Figure Legend from <i>EGFR</i> Exon 20 Insertion Mutations in Lung Adenocarcinomas: Prevalence, Molecular Heterogeneity, and Clinicopathologic Characteristics
2023Open Access
Supplementary Figure 2 from <i>EGFR</i> Exon 20 Insertion Mutations in Lung Adenocarcinomas: Prevalence, Molecular Heterogeneity, and Clinicopathologic Characteristics
2023Open Access
Supplementary Table 1 from <i>EGFR</i> Exon 20 Insertion Mutations in Lung Adenocarcinomas: Prevalence, Molecular Heterogeneity, and Clinicopathologic Characteristics
2023Open Access
Supplementary Figure 1 from <i>EGFR</i> Exon 20 Insertion Mutations in Lung Adenocarcinomas: Prevalence, Molecular Heterogeneity, and Clinicopathologic Characteristics
2023Open Access
page 1 of 8Next →

Frequent Co-authors

David Fenyö(18), Alexey I. Nesvizhskii(17), Li Ding(17), Francesca Petralia(16), Ana I. Robles(16), Weiping Ma(15), Antonio Colaprico(15), Mehdi Mesri(15), Henry Rodriguez(15), Chet Birger(15), Anna Calinawan(15), Felipe da Veiga Leprevost(14), Pei Wang(14), D.R. Mani(14), Amanda G. Paulovich(14), Dmitry Rykunov(14), Yize Li(13), Gilbert S. Omenn(13), Bing Zhang(13), Marcin Cieślik(13)